While PAK inhibitors, so far, have gained little traction in the clinic due to off target effects on healthy cells, one of the excellent reviewers of this manuscript pointed out that recent work [46] has demonstrated that targeting of PKCiota-PAK1 signaling pathways is highly effective in preclinical models of NSCLC. The gene discussed is PAK1; the disease is non-small cell lung carcinoma.